Berberine, an
isoquinoline alkaloid from Coptidis Rhizoma, has been characterized as a potential anticancer
drug due to its good anti-
tumor effects. However, the molecular mechanisms involved in anti-
gastric cancer remain poorly understood. Herein, the role of
berberine in
gastric cancer suppression by inducing
cytostatic autophagy in vitro and in vivo was first investigated. Results showed that
berberine induced an obvious growth inhibitory effect on
gastric cancer BGC-823 cells without toxicity to human peripheral blood mononuclear cells. Treatment with
berberine triggered cell autophagy, as demonstrated by the punctuate distribution of
monodansylcadaverine staining and GFP-LC3, as well as the LC3-II,
Beclin-1 and p-ULK1 promotion, and p62 degradation. Inhibition of autophagy by 3-MA, CQ, Baf-A1 and BECN1
siRNA obviously increased cell viability of
berberine-exposed
gastric cancer cells, which confirmed the anti-
cancer role of autophagy induced by
berberine. Mechanistic studies showed that
berberine inhibited mTOR, Akt and MAPK (ERK, JNK and p38) pathways thereby inducing autophagy. Inhibition of above pathways increases
berberine induced autophagy and cytotoxicity. Interestingly, mTOR/
p70S6K was inhibited by the MAPK but not Akt. Furthermore, inhibition of autophagy reversed
berberine down-regulated mTOR, Akt and MAPK. In xenografts, the
berberine induced autophagy leads to suppression of
tumor proliferation with no side-effect, and western blotting displayed an apparent attenuation of p-mTOR, p-p70S6K, p-Akt, p-ERK, p-JNK and p-p38 in
tumors from
berberine treated mice. Briefly, these results indicated that
berberine repressed human
gastric cancer cell growth in vitro and in vivo by inducing
cytostatic autophagy via inhibition of MAPK/mTOR/
p70S6K and Akt, and provided a molecular basis for the treatment of
gastric cancer.